IPO
Product and Service revenue up 29% year-on-year
OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.
PhaseBio Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 9,200,000 shares of common stock at a price to the public of $5.00 per share, for total gross proceeds of approximately $46.0 million.
Osmotica Pharmaceuticals plc today announced the pricing of its initial public offering of 6,650,000 ordinary shares at a public offering price of $7.00 per share.
Aclaris Therapeutics, Inc. today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share.
MDxHealth SA (Euronext Brussels: MDXH) (“MDxHealth” or the “Company”), announced that it received on October 12, 2018 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions (the “Belgian Transparency Act”).
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Orchard Therapeutics, with locations in Boston and London, UK, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for OTL-300, a lentiviral gene therapy for transfusion-dependent beta-thalassemia (TDBT).
Despite an ongoing lawsuit over alleged theft of intellectual property, San Francisco-based Twist Bioscience plans to go public with an $86 million initial public offering.
PRESS RELEASES